About Us
BRIDGING SCIENCE AND PATIENTS
Our History
We seek to grow our business through the addition of a research platform to our established development platform.
-
2020-
02
In-licensing agreement for our back-eye disease drug candidate
2019-
12
Listed on the KOSDAQ
-
07
Out-licensing agreement of BBT-877 with Boehringer Ingelheim
-
04
BBT-401 first administered to patients in Phase 2 clinical studies in the United States
-
03
Series C closed
-
02
Initiated Phase 1 clinical trial for BBT-877 in the United States
-
01
FDA orphan drug designation for BBT-877 (IPF) In-licensing agreement for BBT-176
2018-
12
Out-licensing agreement for BBT-401 with Daewoong Pharmaceuticals (22 Asian countries)
-
10
Completed Phase 1 clinical studies for BBT-401
-
05
In-licensing agreement for BBT-931
2017-
09
Series B closed
-
05
In-licensing agreement for BBT-877
-
02
-
2016-
12
Establishment of our US subsidiary
-
07
Series A closed
2015-
10
In-licensing agreement for BBT-401
-
09
Corporate establishment
-
12